Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy.

MacLeod AK, Lin, Huang JT, McLaughlin LA, Henderson CJ, Wolf CR.

Clin Cancer Res. 2018 May 1;24(9):2138-2147. doi: 10.1158/1078-0432.CCR-17-3555. Epub 2018 Feb 6.

PMID:
29437786
2.

Stereotactic Radiosurgery: The Revolutionary Advance in the Treatment of Spine Metastases.

Robin AM, Yamada Y, McLaughlin LA, Schmitt A, Higginson D, Lis E, Bilsky MH.

Neurosurgery. 2017 Sep 1;64(CN_suppl_1):59-65. doi: 10.1093/neuros/nyx222. No abstract available.

PMID:
28899042
3.

The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery.

Yamada Y, Katsoulakis E, Laufer I, Lovelock M, Barzilai O, McLaughlin LA, Zhang Z, Schmitt AM, Higginson DS, Lis E, Zelefsky MJ, Mechalakos J, Bilsky MH.

Neurosurg Focus. 2017 Jan;42(1):E6. doi: 10.3171/2016.9.FOCUS16369.

4.

Frequency of symptomatic vertebral body compression fractures requiring intervention following single-fraction stereotactic radiosurgery for spinal metastases.

Virk MS, Han JE, Reiner AS, McLaughlin LA, Sciubba DM, Lis E, Yamada Y, Bilsky M, Laufer I.

Neurosurg Focus. 2017 Jan;42(1):E8. doi: 10.3171/2016.10.FOCUS16359.

PMID:
28041324
5.

Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.

MacLeod AK, McLaughlin LA, Henderson CJ, Wolf CR.

Drug Metab Dispos. 2017 Jan;45(1):17-22. Epub 2016 Oct 18.

6.

The Role of Protein-Protein and Protein-Membrane Interactions on P450 Function.

Scott EE, Wolf CR, Otyepka M, Humphreys SC, Reed JR, Henderson CJ, McLaughlin LA, Paloncýová M, Navrátilová V, Berka K, Anzenbacher P, Dahal UP, Barnaba C, Brozik JA, Jones JP, Estrada DF, Laurence JS, Park JW, Backes WL.

Drug Metab Dispos. 2016 Apr;44(4):576-90. doi: 10.1124/dmd.115.068569. Epub 2016 Feb 5. Review.

7.

Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models.

MacLeod AK, McLaughlin LA, Henderson CJ, Wolf CR.

Cancer Res. 2015 Nov 1;75(21):4573-81. doi: 10.1158/0008-5472.CAN-15-1454. Epub 2015 Sep 11.

8.

Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model.

Scheer N, Kapelyukh Y, Rode A, Oswald S, Busch D, McLaughlin LA, Lin D, Henderson CJ, Wolf CR.

Drug Metab Dispos. 2015 Nov;43(11):1679-90. doi: 10.1124/dmd.115.065656. Epub 2015 Aug 11.

9.

Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action.

Kostov RV, Knatko EV, McLaughlin LA, Henderson CJ, Zheng S, Huang JT, Honda T, Dinkova-Kostova AT.

Biochem Biophys Res Commun. 2015 Sep 25;465(3):402-7. doi: 10.1016/j.bbrc.2015.08.016. Epub 2015 Aug 8.

10.

Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.

Henderson CJ, McLaughlin LA, Scheer N, Stanley LA, Wolf CR.

Mol Pharmacol. 2015 Apr;87(4):733-9. doi: 10.1124/mol.114.097394. Epub 2015 Feb 5.

11.

HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents.

McMahon M, Campbell KH, MacLeod AK, McLaughlin LA, Henderson CJ, Wolf CR.

PLoS One. 2014 Nov 26;9(11):e114055. doi: 10.1371/journal.pone.0114055. eCollection 2014.

12.

Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability.

Henderson CJ, McLaughlin LA, Osuna-Cabello M, Taylor M, Gilbert I, McLaren AW, Wolf CR.

Biochem J. 2015 Feb 1;465(3):479-88. doi: 10.1042/BJ20140582.

PMID:
25377919
13.

Deletion of 30 murine cytochrome p450 genes results in viable mice with compromised drug metabolism.

Scheer N, McLaughlin LA, Rode A, Macleod AK, Henderson CJ, Wolf CR.

Drug Metab Dispos. 2014 Jun;42(6):1022-30. doi: 10.1124/dmd.114.057885. Epub 2014 Mar 26.

14.

A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.

Henderson CJ, McLaughlin LA, Finn RD, Ronseaux S, Kapelyukh Y, Wolf CR.

Drug Metab Dispos. 2014 Jan;42(1):70-7. doi: 10.1124/dmd.113.055277. Epub 2013 Oct 10.

15.

Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.

Henderson CJ, McLaughlin LA, Wolf CR.

Mol Pharmacol. 2013 Jun;83(6):1209-17. doi: 10.1124/mol.112.084616. Epub 2013 Mar 25.

16.

NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.

Riddick DS, Ding X, Wolf CR, Porter TD, Pandey AV, Zhang QY, Gu J, Finn RD, Ronseaux S, McLaughlin LA, Henderson CJ, Zou L, Flück CE.

Drug Metab Dispos. 2013 Jan;41(1):12-23. doi: 10.1124/dmd.112.048991. Epub 2012 Oct 19.

17.

Biochemical comparison of Anopheles gambiae and human NADPH P450 reductases reveals different 2'-5'-ADP and FMN binding traits.

Lian LY, Widdowson P, McLaughlin LA, Paine MJ.

PLoS One. 2011;6(5):e20574. doi: 10.1371/journal.pone.0020574. Epub 2011 May 31.

18.

Cytochrome b5 null mouse: a new model for studying inherited skin disorders and the role of unsaturated fatty acids in normal homeostasis.

Finn RD, McLaughlin LA, Hughes C, Song C, Henderson CJ, Roland Wolf C.

Transgenic Res. 2011 Jun;20(3):491-502. doi: 10.1007/s11248-010-9426-1. Epub 2010 Jul 30.

19.

Deletion of microsomal cytochrome b5 profoundly affects hepatic and extrahepatic drug metabolism.

McLaughlin LA, Ronseaux S, Finn RD, Henderson CJ, Roland Wolf C.

Mol Pharmacol. 2010 Aug;78(2):269-78. doi: 10.1124/mol.110.064246. Epub 2010 Apr 29. Erratum in: Mol Pharmacol. 2014 Jan;85(1)186. Dosage error in article text.

20.

An observational study on the effectiveness of point-of-use chlorination.

McLaughlin LA, Levy K, Beck NK, Shin GA, Meschke JS, Eisenberg JN.

J Environ Health. 2009 Apr;71(8):48-53.

21.

Defining the in Vivo Role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5.

Finn RD, McLaughlin LA, Ronseaux S, Rosewell I, Houston JB, Henderson CJ, Wolf CR.

J Biol Chem. 2008 Nov 14;283(46):31385-93. doi: 10.1074/jbc.M803496200. Epub 2008 Sep 19.

22.

Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening.

McLaughlin LA, Dickmann LJ, Wolf CR, Henderson CJ.

Drug Metab Dispos. 2008 Jul;36(7):1322-31. doi: 10.1124/dmd.108.021261. Epub 2008 Apr 17.

23.

Characterization of inhibitors and substrates of Anopheles gambiae CYP6Z2.

McLaughlin LA, Niazi U, Bibby J, David JP, Vontas J, Hemingway J, Ranson H, Sutcliffe MJ, Paine MJ.

Insect Mol Biol. 2008 Apr;17(2):125-35. doi: 10.1111/j.1365-2583.2007.00788.x.

PMID:
18353102
24.

Anopheles gambiae P450 reductase is highly expressed in oenocytes and in vivo knockdown increases permethrin susceptibility.

Lycett GJ, McLaughlin LA, Ranson H, Hemingway J, Kafatos FC, Loukeris TG, Paine MJ.

Insect Mol Biol. 2006 Jun;15(3):321-7.

PMID:
16756551
25.

Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.

McLaughlin LA, Paine MJ, Kemp CA, Maréchal JD, Flanagan JU, Ward CJ, Sutcliffe MJ, Roberts GC, Wolf CR.

J Biol Chem. 2005 Nov 18;280(46):38617-24. Epub 2005 Sep 14.

26.

Nasal implants: autogenous, semisynthetic, and synthetic.

Romo T 3rd, McLaughlin LA, Levine JM, Sclafani AP.

Facial Plast Surg Clin North Am. 2002 May;10(2):155-66. Review. No abstract available.

PMID:
15062318
27.

Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Flanagan JU, Maréchal JD, Ward R, Kemp CA, McLaughlin LA, Sutcliffe MJ, Roberts GC, Paine MJ, Wolf CR.

Biochem J. 2004 Jun 1;380(Pt 2):353-60.

28.

Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.

Flanagan JU, McLaughlin LA, Paine MJ, Sutcliffe MJ, Roberts GC, Wolf CR.

Biochem J. 2003 Mar 15;370(Pt 3):921-6.

29.

Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.

Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, Wolf CR.

J Biol Chem. 2003 Feb 7;278(6):4021-7. Epub 2002 Nov 22.

30.

Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: an intralaboratory comparison.

Friedberg T, Pritchard MP, Bandera M, Hanlon SP, Yao D, McLaughlin LA, Ding S, Burchell B, Wolf CR.

Drug Metab Rev. 1999 May;31(2):523-44. Review.

PMID:
10335451
31.

Asian and Pacific Islander cultural values: considerations for health care decision making.

McLaughlin LA, Braun KL.

Health Soc Work. 1998 May;23(2):116-26. Review.

PMID:
9598394
32.

Myotonia congenita. A review of four cases.

Winters JL, McLaughlin LA.

J Bone Joint Surg Am. 1970 Oct;52(7):1345-50. No abstract available.

PMID:
5469190
33.

The diagnosis and treatment of Duchenne muscular dystrophy.

Winters JL, McLaughlin LA Jr.

South Med J. 1970 May;63(5):530-2. No abstract available.

PMID:
5446821
34.

DRUG-INDUCED DIABETES.

MCLAUGHLIN LA Jr.

J La State Med Soc. 1963 Oct;115:355-7. No abstract available.

PMID:
14053316
35.

GIARDIAL DUODENITIS: CLINICAL MANIFESTATIONS OF GIARDIASIS IN CHILDREN (REPORT OF THREE CASES).

MCLAUGHLIN LA Jr.

J La State Med Soc. 1963 Oct;115:350-4. No abstract available.

PMID:
14053315
36.

Alkofanone in the treatment of simple diarrhea in children.

RUSS JD, McLAUGHLIN LA, MILLER J.

Curr Ther Res Clin Exp. 1961 Oct;3:427-30. No abstract available.

PMID:
14495383
37.

Encephalopathy in a child following exposure to malathion.

MCLAUGHLIN LA Jr, SYNDER CH.

Ochsner Clin Rep. 1956 Jan;2(1):37-40. No abstract available.

PMID:
13297314

Supplemental Content

Loading ...
Support Center